Your browser doesn't support javascript.
loading
Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper.
Perucca, Emilio; French, Jacqueline A; Aljandeel, Ghaieb; Balestrini, Simona; Braga, Patricia; Burneo, Jorge G; Felli, Augustina Charway; Cross, J Helen; Galanopoulou, Aristea S; Jain, Satish; Jiang, Yuwu; Kälviäinen, Reetta; Lim, Shih Hui; Meador, Kimford J; Mogal, Zarine; Nabbout, Rima; Sofia, Francesca; Somerville, Ernest; Sperling, Michael R; Triki, Chahnez; Trinka, Eugen; Walker, Matthew C; Wiebe, Samuel; Wilmshurst, Jo M; Wirrell, Elaine; Yacubian, Elza Márcia; Kapur, Jaideep.
Afiliación
  • Perucca E; Department of Medicine, The University of Melbourne (Austin Health), Heidelberg, Victoria, Australia.
  • French JA; Department of Neuroscience, Monash University, Melbourne, Victoria, Australia.
  • Aljandeel G; NYU Grossman School of Medicine and NYU Langone Health, New York, New York, USA.
  • Balestrini S; Faculty of Epileptology, Iraqi Council for Medical Specializations, Medical City, Baghdad, Iraq.
  • Braga P; Neuroscience Department, Meyer Children's Hospital, Florence, Italy.
  • Burneo JG; University of Florence, Florence, Italy.
  • Felli AC; Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK.
  • Cross JH; Institute of Neurology, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
  • Galanopoulou AS; Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Jain S; Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Jiang Y; Neuroepidemiology Unit, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Kälviäinen R; 37 Military Hospital, Accra, Ghana.
  • Lim SH; Developmental Neurosciences Research and Teaching Department, UCL NIHR BRC Great Ormond Street Institute of Child Health, London, UK.
  • Meador KJ; Department of Neurology, Great Ormond Street Hospital, London, UK.
  • Mogal Z; Young Epilepsy, Lingfield, UK.
  • Nabbout R; Isabelle Rapin Division of Child Neurology, Saul R. Korey Department of Neurology, Dominick P Purpura Department of Neuroscience, Albert Einstein College of Medicine, New York, New York, USA.
  • Sofia F; Indian Epilepsy Centre, New Delhi, India.
  • Somerville E; Department of Pediatrics and Pediatric Epilepsy Center, Peking University First Hospital, Beijing, China.
  • Sperling MR; Pediatric Epilepsy Center, Peking University First Hospital, Beijing, China.
  • Triki C; Beijing Key Laboratory of Molecular Diagnosis and Study on Pediatric Genetic Diseases, Beijing, China.
  • Trinka E; Key Laboratory for Neuroscience, Ministry of Education/National Health and Family Planning Commission, Peking University, Beijing, China.
  • Walker MC; Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing, China.
  • Wiebe S; Kuopio Epilepsy Center, Kuopio University Hospital, Kuopio, Finland.
  • Wilmshurst JM; Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Wirrell E; National Neuroscience Institute, Singapore, Singapore.
  • Yacubian EM; Duke-National University of Singapore Medical School, Singapore, Singapore.
  • Kapur J; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Epilepsia ; 65(3): 533-541, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38279786
ABSTRACT
A variety of terms, such as "antiepileptic," "anticonvulsant," and "antiseizure" have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English-language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named "antiseizure medications". This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term "antiseizure" to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having "antiepileptogenic" or "disease-modifying" effects. A more-refined terminology to describe precisely these actions needs to be developed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsia Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Epilepsia Año: 2024 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsia Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Epilepsia Año: 2024 Tipo del documento: Article País de afiliación: Australia